1978.09 – 1982.07 复旦大学化学系, 有机化学专业，理学学士
1987.09 – 1990.03 日本东京大学工学部, 工业化学专业，工学硕士
1990.03 – 1993.03 日本东京大学工学部, 工业化学专业，工学博士
1993.04 – 1996.08 哈佛大学, 化学和化学生物系, 博士后研究员
1982.08 – 1987.05 世界卫生组织人类生殖研究中心/上海计划生育研究所, 药物研究室，助理研究员
1998.09 – 2010.10 Sepracor公司, 药物研发及临床前研究部 (美国, 马萨诸塞州)
2008-2010 资深总监
2005-2008 总监
2001-2005 副总监
2000-2001 资深科学家
1998-2000 科学家
2010.10 – 2012.05 Sunovion公司, 临床前研究及转化医学部 (美国, 马萨诸塞州)资深总监
2012.06 –至今复旦大学药学院，教授
教授
博士生导师、上海市药物研发协同创新中心主任、复旦大学医药健康产业发展战略研究中心主任
参与和主持了各类药物的研究与开发工作，其中4个化合物获美国FDA认准进入临床试验，曾参与避孕药的研发，其中一个药物获得中国FDA 批准上市
1. 中枢神经系统疾病诊断治疗药物的合理设计、合成与研究开发
2. 恶性肿瘤治疗药物的研究开发
3. 药物发现新方法（合成新方法、成药性、结构生物学）的研究开发
4. 药物研究中转化医学手段的探索研究
1. Zhang, D.G.; Gui, J.W.; Kong, L.H.; Hu, C.Y.; Kou, X.M.; Wang, B.Y.; Duan, S.L.; Liu, M; Li, Z.X.; Luo, J.W.; Tang, S.Y.; Xiao, H; Du, Z.Y.; Xie, Q.; Liu, J.G.*; Shao, L.M.*; Fu, W.*; Wang, Y.J.*; Li, W.* Design, synthesis, and biological activity of novel para-substituted phenylamino and phenyl derivatives of northebaine as selective delta opioid receptor agonists. Bioorg Med Chem. 2025 Aug 28;130: 118373.
2. Zhi, X. C.; Li, Q.; Shao, L. M.* Approvals by the China NMPA in 2024. Nat Rev Drug Discov 2025, 24, 160-161.
3. Zhang, D. G.; Xiang, W.; Liu, J.; Li, W.*; Qiao, Z.*; Wang, K. W.*; Shao, L. M.* Design, synthesis, and structure-activity relationship of 5,7- dimethylbenzo[d]thiazoles as novel Kv7.2/7.3 activators with antiepileptic effects. Eur J Med Chem, 2025, 292, 117660.
4. Li, N.; Luo, C. F.; Liu, Y. F.; Duan, S. L.; Wang, X.; Cheng, H.; Xue, D. Q.; Wang, Y. T.*; Li, W.*; Hou, S. X.*; Shao, L. M.* Design, synthesis and biological evaluation of (E)-4-(2-((1H-indol-5-yl)methylene) hydrazineyl)-5,6,7,8-tetrahydropyrido [4′,3′:4,5] thieno[2,3-d]pyrimidine derivatives as Arf1-GEFs inhibitors for the treatment of colon cancer. Eur J Med Chem, 2025, 297, 117962.
5. Kong, L. H.; Yao, S. Y.; Zhang, D. G.; Gui, J. W.; Chen, B. Y.; Liu, M.; Tang, S. Y.; Hu, C. Y.; Duan, S. L.; Wang, B. Y.; Li, Z. X.; Shen, Y. Q.; Lan, Y. J.; Liu, X. N.; Du, Z. Y.; Liu, Z. H.; Xie, Q.; Liu, A. N.; Chai, J. R.; Liu, J. G. *; Shao, L. M. *; Fu, W.; Wang, Y. J. *; Li, W. * Structure-Activity Relationship of N-Cyclopropylmethyl-7α-[-(arylcarboxamido)phenyl]-6,14-ethano-tetrahydronorthebaines as Potent and SelectiveKappa Opioid Receptor Agonists. J Med Chem, 2025, 68(15), 15889–15909.
6. Gu, Y. G.; Jing, R.; Kaitin, K. I.; Shao, L. M. * The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China. Nat Rev Drug Discov 2025, 24, 492-493.
7. Tang, S.Y.; Hu, S.Y.; Feng, LJ..; Kong, L.M; Gui, J.W.; Zhang, Y.; Liu, Z. H.; Zhang, D.; Liu, A. A.; Liu, X.; Hu, C.; Lan, Y.J.; Liu, X.N.; Li, Z.X.; Liu, P.W.; Duan, S.L.; Du, Z.Y.; Liu, M.; Xie, Q.; Liu, J.G. *; Shao, L.M. *; Fu, W.; Wang, Y.J. *; Li, W. * Structure-activity relationship analysis of meta-substituted N-cyclopropylmethyl-nornepenthones with mixed KOR/MOR activities. Eur J Med Chem 2025, 289, 117449.
8. Zhi, X. C.; Li, Q.; Shao, L. M. * Approvals by the China NMPA in 2023. Nat Rev Drug Discov 2024, 23, 164-165.
9. Li, Z. X.; Ye, R. F.; He, Q.; Lu, J. S.; Sun, Y. T.; Sun, X. J.; Tang, S. Y.; Hu, S. Y.; Chai, J. R.; Kong, L. H.; Liu, X. N.; Chen, J.; Fang, Y.; Lan, Y. J.; Xie, Q.; Liu, J. G. *; Shao, L. M. *; Fu, W.; Wang, Y. J. *; Li, W. * Discovery of an Ortho-Substituted-Cyclopropylmethyl-7α-phenyl-6,14-ethano-tetrahydronorthebaine Derivative as a Selective and Potent Kappa Opioid Receptor Agonist with Subsided Sedative Effect. J Med Chem 2024, 67, 7112-7129.
10. Ge, Q. W.; Zhang, X.; Kaitin, K. I.; Shao, L. M.* Development of Chinese innovative drugs in the USA. Nat Rev Drug Discov 2024, 23, 412-413.
11. Cheng, H.; Liu, R. Q.; Fang, S. Y.; Li, Z. X.; Zhang, D. G.; Zhang, X.; Chen, W. F.; Chen, H. X.; Kang, L. Y.; Wang, J.; Xu, Y. L.; Song, S. L.; Shao, L. M. * Synthesis of easily-modified and useful dibenzo-[b,d]azepines by palladium(ii)-catalyzed cyclization/addition with a green solvent. Chem Commun 2024, 60, 3587-3590.
12. Kong, L. H.; Ning, K.; Liu, X.; Lu, J. S.; Chen, B. Y.; Ye, R. R.; Li, Z. X.; Jiang, S.; Tang, S. Y.; Chai, J. R.; Fang, Y.; Lan, Y. J.; Mai, X. B.; Xie, Q.; Liu, J. G. *; Shao, L. M. *; Fu, W.; Wang, Y. J. *; Li, W. * Reversal of subtype-selectivity and function by the introduction of a para-benzamidyl substituent to N-cyclopropylmethyl nornepenthone. Eur J Med Chem 2023, Oct 5;258:115589.
13. Tang, S. Y.; Xue, Y. J.; Dengqi, X.; Shao, L. M. * Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem 2023, Jan 5;245(Pt 2):114901.
14. Ouyang, X. S.; Su, M.; Xue, D. Q.; Dong, L. Y.; Niu, H. L.; Li, W.*; Liu, Y. N.*; Wang, K. W.*; Shao, L. M.* Design, synthesis, and biological evaluation of acyl sulfonamide derivatives with spiro cycles as NaV1.7 inhibitors for antinociception. Bioorg Med Chem 2023;86:117290.
15. Ge, Q. W.; Xu, L. L.; DiMasi, J. A.; Kaitin, K. I.; Shao, L. M.* Impact of regulatory system changes on the availability of innovative drugs in China. Nat Rev Drug Discov 2023, 22(5):344-345.
16. Kong, L. H.; Li, Q.; Kaitin, K. I.; Shao, L. M.* Innovation in the Chinese pharmaceutical industry. Nat Rev Drug Discov 2023, 22, 12-13.
17. Kong, L. H.; He, Q.; Li, Q.; Schreiber, R.; Kaitin, K. I.; Shao, L. M.* Rapid progress in neuroimaging technologies fuels central nervous system translational medicine. Drug Discov Today 2023, Mar;28(3):103485.
18. Kong, L. H.; Shu, X. L.; Tang, S. Y.; Ye, R. R.; Sun, H. J.; Jiang, S.; Li, Z. X.; Chai, J. R.; Fang, Y.; Lan, Y. J.; Yu, L. Q.; Xie, Q.; Fu, W.; Wang, Y. J. *; Li, W. *; Qiu, Z. B.; Liu, J. G.*; Shao, L. M.* SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity. J Med Chem 2022, 65, 10377-10392.
19. Liang, Q. Q.; Qiao, Z.; Zhou, Q. Q.*; Xue, D. Q.; Wang, K. W. ; Shao, L. M.* Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects In Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core. J Med Chem 2022, 65, 11658-11678.
20. Dong, L. Y.; Zhou, Q. Q.; Liang, Q. Q.; Qiao, Z.; Liu, Y. N.; Shao, L. M.*; Wang, K. W.* Identification of a Partial and Selective TRPV1 Agonist CPIPC for Alleviation of Inflammatory Pain. Molecules 2022, 27.
21. Xue, D. Q.; Liu, Y. N.*; Zheng, Y. L.; Niu, H. L.; Dong, L. Y.; Ouyang, X. S.; Song, S. Y.; Zhang, D. G.; Ge, Q. W.; Wang, K. W.; Shao, L. M.* Design and synthesis of novel alpha-aminoamides derivatives as Nav1.7 inhibitors for antinociception. Chinese Chem Lett 2022, 33, 1643-1646.
22. Qiao, Z.; Tang, S. Y.; Guan, J. L.; Yin, Z. J.; Zhu, C.; Zhou, Q. Q.; Shao, L. M.* Design and development of selective competitive fluorescent ligands for the detection and visualization of Kv7.2/7.3 in vitro. Chem Commun 2022, 58, 3791-3794.
